Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2021-09-02
Target enrollment:
Participant gender:
Summary
This phase II trial studies the effect of larotrectinib in treating patients with NTRK gene
amplification positive solid tumors that have spread to nearby tissues or lymph nodes
(locally advanced) or other places in the body (metastatic). Larotrectinib may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth.